newsfilter
← Latest News
GlobeNewswire·

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced